DexCom Announces Upcoming Conference Presentation
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Canaccord Genuity Reiterates Buy on DexCom (DXCM) Following FDA Approval of DexCom's G5 Mobile
December 21, 2016 10:17 AM ESTCanaccord Genuity reiterated a Buy rating and $70.00 price target on DexCom (NASDAQ: DXCM) following the company's announced FDA approval of DexCom's G5 mobile for "non-adjunctive use". Notably, the FDA stated that although G5 "still requires two finger-stick calibrations, it eliminates the need for any additional finger-stick blood... More
